Palvella Therapeutics (PVLA) Institutional Ownership $24.12 +0.29 (+1.22%) As of 01:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Palvella Therapeutics (NASDAQ:PVLA)CurrentInstitutional OwnershipPercentage40.11%Number ofInstitutional Buyers(last 12 months)22TotalInstitutional Inflows(last 12 months)$67.97MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$786.63K Get PVLA Insider Trade Alerts Want to know when executives and insiders are buying or selling Palvella Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data PVLA Institutional Buying and Selling by Quarter Palvella Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails6/27/2025Goldman Sachs Group Inc.19,053$533K0.0%N/A0.172% 5/16/2025Woodline Partners LP194,167$5.44M0.0%N/A1.758% 5/16/2025Goldman Sachs Group Inc.19,053$533K0.0%N/A0.173% 5/16/2025Millennium Management LLC269,837$7.55M0.0%N/A2.444% 5/16/2025AWM Investment Company Inc.69,416$1.94M0.3%N/A0.629% 5/15/2025Frazier Life Sciences Management L.P.690,012$19.31M0.9%+5.5%6.248% 5/15/2025DAFNA Capital Management LLC43,348$1.21M0.3%-39.3%0.393% 5/6/2025Royce & Associates LP71,514$2.00M0.0%N/A0.648% 4/25/2025Strid Group LLC29,219$818K0.1%N/A0.265% 4/23/2025Spire Wealth Management2,516$70K0.0%N/A0.023% Get the Latest News and Ratings for PVLA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/19/2025Toronto Dominion Bank13,211$159K0.0%N/A0.118% 2/18/2025Frazier Life Sciences Management L.P.653,892$7.85M0.3%N/A5.828% 2/17/2025Toronto Dominion Bank13,211$159K0.0%N/A0.118% 2/17/2025Suvretta Capital Management LLC714,463$8.57M0.3%N/A6.367% 2/17/2025DAFNA Capital Management LLC71,452$857K0.2%N/A0.637% 2/17/2025Cresset Asset Management LLC20,911$251K0.0%N/A0.186% 2/17/2025Citadel Advisors LLC10,408$125K0.0%N/A0.093% 2/17/2025BVF Inc. IL696,555$8.36M0.3%N/A6.208% 2/17/2025Adams Street Partners LLC409,666$4.92M4.4%N/A3.651% 2/14/2025Samsara BioCapital LLC679,486$8.15M1.1%N/A6.056% 2/14/2025Nantahala Capital Management LLC250,062$3.00M0.1%N/A2.229% 2/14/2025Blue Owl Capital Holdings LP250,062$3.00M0.7%N/A2.229% 2/13/2025Renaissance Technologies LLC21,371$256K0.0%N/A0.190% 2/13/2025ADAR1 Capital Management LLC144,641$1.74M0.3%N/A1.289% 2/12/2025Geode Capital Management LLC14,270$171K0.0%N/A0.127% 2/7/2025BML Capital Management LLC42,130$506K0.3%N/A0.375% (Data available from 1/1/2016 forward) PVLA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PVLA shares? During the previous two years, 22 institutional investors and hedge funds held shares of Palvella Therapeutics. The most heavily invested institutionals were Frazier Life Sciences Management L.P. ($19.31M), Suvretta Capital Management LLC ($8.57M), BVF Inc. IL ($8.36M), Samsara BioCapital LLC ($8.15M), Millennium Management LLC ($7.55M), Woodline Partners LP ($5.44M), and Adams Street Partners LLC ($4.92M).Learn more on Palvella Therapeutics' institutional investors. What percentage of Palvella Therapeutics' stock is owned by institutional investors? 40.11% of Palvella Therapeutics' stock is owned by institutional investors. Learn more on PVLA's institutional investor holdings. Which institutional investors have been buying Palvella Therapeutics' stock? Of the 22 institutional investors that purchased Palvella Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Suvretta Capital Management LLC ($714.46K), BVF Inc. IL ($696.56K), Frazier Life Sciences Management L.P. ($690.01K), Samsara BioCapital LLC ($679.49K), Adams Street Partners LLC ($409.67K), Millennium Management LLC ($269.84K), and Nantahala Capital Management LLC ($250.06K). How much institutional buying is happening at Palvella Therapeutics? Institutional investors have bought a total of 4,716,686 shares in the last 24 months. This purchase volume represents approximately $67.97M in transactions. Which of Palvella Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Palvella Therapeutics stock in the last 24 months: DAFNA Capital Management LLC ($28.10K). How much institutional selling is happening at Palvella Therapeutics? Institutional investors have sold a total of 28,104 shares in the last 24 months. This volume of shares sold represents approximately $786.63K in transactions. Related Companies WVE Institutional Ownership ABCL Institutional Ownership DYN Institutional Ownership ELVN Institutional Ownership AUPH Institutional Ownership ARDX Institutional Ownership VERV Institutional Ownership COLL Institutional Ownership AKBA Institutional Ownership NRIX Institutional Ownership This page (NASDAQ:PVLA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
